GERIMAL Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Gerimal, and what generic alternatives are available?
Gerimal is a drug marketed by Watson Labs and is included in three NDAs.
The generic ingredient in GERIMAL is ergoloid mesylates. There are four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ergoloid mesylates profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Gerimal
A generic version of GERIMAL was approved as ergoloid mesylates by SUN PHARM INDUSTRIES on October 31st, 1991.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for GERIMAL?
- What are the global sales for GERIMAL?
- What is Average Wholesale Price for GERIMAL?
Summary for GERIMAL
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 4 |
Formulation / Manufacturing: | see details |
DailyMed Link: | GERIMAL at DailyMed |
![GERIMAL drug patent expirations Drug patent expirations by year for GERIMAL](/p/graph/s/t/GERIMAL-patent-expirations.png)
US Patents and Regulatory Information for GERIMAL
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Watson Labs | GERIMAL | ergoloid mesylates | TABLET;ORAL | 088207-001 | Mar 22, 1984 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Watson Labs | GERIMAL | ergoloid mesylates | TABLET;SUBLINGUAL | 086189-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Watson Labs | GERIMAL | ergoloid mesylates | TABLET;SUBLINGUAL | 086188-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |